Stockscreener 앱 받기
3.90
0.78%
0.03
시간 외 거래:
3.95
0.05
+1.28%
전일 마감가:
$3.87
열려 있는:
$3.86
하루 거래량:
745.61K
Relative Volume:
0.91
시가총액:
$322.76M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+1.04%
1개월 성능:
+0.26%
6개월 성능:
+119.10%
1년 성능:
+0.00%
1일 변동 폭
$3.78
$3.975
1주일 범위
$3.33
$3.99
52주 변동 폭
$1.42
$4.225
Atyr Pharma Inc Stock (ATYR) Company Profile
명칭
Atyr Pharma Inc
전화
(858) 731-8389
주소
10240 SORRENTO VALLEY ROAD, SAN DIEGO
ATYR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
3.90 | 322.76M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 120.86B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 77.62B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.62B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.20B | 3.30B | -501.07M | 1.03B | -2.1146 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-04 | 개시 | Wells Fargo | Overweight |
| 2024-09-05 | 개시 | Jefferies | Buy |
| 2023-07-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-10-12 | 개시 | RBC Capital Mkts | Outperform |
| 2021-09-21 | 개시 | Piper Sandler | Overweight |
| 2021-05-10 | 개시 | Laidlaw | Buy |
| 2020-08-17 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | 개시 | ROTH Capital | Buy |
| 2020-03-02 | 개시 | Oppenheimer | Outperform |
| 2018-02-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-09-07 | 개시 | Piper Jaffray | Overweight |
| 2016-12-13 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2015-12-16 | 개시 | Citigroup | Neutral |
| 2015-06-01 | 개시 | Citigroup | Buy |
| 2015-06-01 | 개시 | JP Morgan | Overweight |
모두보기
Atyr Pharma Inc 주식(ATYR)의 최신 뉴스
Stocks of Atyr Pharma Inc (ATYR) are poised to climb above their peers - SETE News
Recent Insider Activity Suggests Potential Gains for Atyr Pharma Inc (ATYR) - Knox Daily
How to interpret Atyr Pharma Inc (ATYR)’s stock chart patterns - US Post News
aTyr Pharma CFO Broadfoot sells $4,740 in stock - MSN
Atyr Pharma's general counsel Nancy Denyes sells $3,398 in stock - MSN
Trading Day Review: Atyr Pharma Inc (ATYR) Loses Momentum, Closing at 3.57 - The Dwinnex
JPMorgan Chase & Co. Boosts Holdings in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Increases By 25.0% - MarketBeat
Head to Head Contrast: CERo Therapeutics (NASDAQ:CERO) versus Atyr PHARMA (NASDAQ:ATYR) - Defense World
Here's Why We're Watching aTyr Pharma's (NASDAQ:ATYR) Cash Burn Situation - Yahoo Finance
aTyr Pharma to Present Three Posters for Efzofitimod at the - GlobeNewswire
Revolutionary Lung Disease Treatment Shows Promise: Major Updates Coming at ATS 2025 - StockTitan
Cantor Fitzgerald Estimates Atyr PHARMA FY2025 Earnings - Defense World
Cantor Fitzgerald Predicts Atyr PHARMA FY2025 Earnings - MarketBeat
Institutional investors are aTyr Pharma, Inc.'s (NASDAQ:ATYR) biggest bettors and were rewarded after last week's US$29m market cap gain - Simply Wall St
Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Expands By 25.0% - MarketBeat
Cantor Fitzgerald Weighs in on Atyr PHARMA FY2024 Earnings - Defense World
Several Insiders Invested In aTyr Pharma Flagging Positive News - Yahoo Finance
aTyr Pharma: Interesting Drug, Difficult Target Market (ATYR) - Seeking Alpha
Atyr PHARMA (NASDAQ:ATYR) Now Covered by Analysts at Cantor Fitzgerald - Defense World
This Toast Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
aTyr Pharma stock soars to 52-week high of $4.16 By Investing.com - Investing.com Canada
Atyr PHARMA (NASDAQ:ATYR) Now Covered by Cantor Fitzgerald - MarketBeat
Head-To-Head Analysis: Atyr PHARMA (NASDAQ:ATYR) versus CG Oncology (NASDAQ:CGON) - Defense World
Atyr PHARMA INC (NASDAQ:ATYR) Sees Significant Increase in Short Interest - MarketBeat
aTyr Pharma stock soars to 52-week high, hits $3.86 By Investing.com - Investing.com Canada
aTyr Pharma stock soars to 52-week high, hits $3.86 - Investing.com
SEC Form 424B5 filed by aTyr Pharma Inc. - Quantisnow
Exploring Three High Growth Tech Stocks In The United States - Simply Wall St
aTyr Pharma, Inc. (NASDAQ:ATYR) is a favorite amongst institutional investors who own 57% - Yahoo Finance
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
aTyr Pharma to Present at JPMorgan Healthcare Conference: Spotlight on Revolutionary tRNA Platform - StockTitan
aTyr Pharma's SWOT analysis: efzofitimod's potential drives stock outlook - Investing.com
aTyr Pharma's SWOT analysis: efzofitimod's potential drives stock outlook By Investing.com - Investing.com Canada
aTyr Pharma expands board with new director appointment By Investing.com - Investing.com Canada
ATyr Pharma, Inc. Appoints Eric Benevich to Its Board of Directors - Marketscreener.com
aTyr Pharma expands board with new director appointment - Investing.com India
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors - The Manila Times
aTyr Pharma Strengthens Board with Neurocrine CCO Eric Benevich, Bolsters Commercial Leadership - StockTitan
aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis - The Manila Times
aTyr Pharma Announces Third Positive DSMB Review for - GlobeNewswire
aTyr Pharma's Efzofitimod Phase 3 Trial Clears Critical Safety Review for Pulmonary Sarcoidosis Treatment - StockTitan
Atyr PHARMA (NASDAQ:ATYR) vs. Quince Therapeutics (NASDAQ:QNCX) Critical Survey - Defense World
aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis - The Manila Times
aTyr Pharma to Present Preclinical Research Demonstrating - GlobeNewswire
aTyr Pharma's Novel Fibrosis Treatment Shows Breakthrough Results in Preclinical Studies - StockTitan
Sarcoidosis Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | Pfizer, United Therapeutics, Xentria, Inc., aTyr Pharma, Inc., Kyorin Pharma, Novartis, Kinevant Sciences - Barchart
Atyr Pharma Inc (ATYR) 재무 분석
Atyr Pharma Inc (ATYR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Atyr Pharma Inc 주식 (ATYR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| DENYES NANCY | General Counsel |
Feb 04 '25 |
Sale |
3.78 |
899 |
3,398 |
26,555 |
| SCHIMMEL PAUL | Director |
Jul 24 '24 |
Buy |
1.93 |
52,300 |
101,038 |
413,023 |
| SCHIMMEL PAUL | Director |
Jul 22 '24 |
Buy |
1.74 |
41,052 |
71,500 |
354,075 |
| SCHIMMEL PAUL | Director |
Jul 23 '24 |
Buy |
1.82 |
6,648 |
12,075 |
360,723 |
| DENYES NANCY | General Counsel |
Jun 05 '24 |
Buy |
1.86 |
5,000 |
9,276 |
22,267 |
| COUGHLIN TIMOTHY | Director |
May 30 '24 |
Buy |
1.75 |
50,000 |
87,500 |
56,000 |
| Broadfoot Jill Marie | Chief Financial Officer |
May 31 '24 |
Buy |
1.79 |
5,000 |
8,950 |
27,960 |
| Shukla Sanjay | President and CEO |
May 31 '24 |
Buy |
1.81 |
20,000 |
36,140 |
136,548 |
1.03%
자본화:
|
볼륨(24시간):